AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02802423
Drug: BLEX 404 Oral Liquid
RxNorm normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
Trial: NCT05359133
Drug: Tetrodotoxin
RxNorm normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
Trial: NCT06524570
Drug: ICI
RxNorm normalized name: Ficin
DrugBank: Taraxacum officinale pollen (DB10755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab and nivolumab
Trial: NCT06109272
Drug: Livmoniplimab
RxNorm normalized name: Livmoniplimab
DrugBank: Livmoniplimab (DB18939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Solution
Trial: NCT06109272
Drug: Budigalimab
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Solution
Trial: NCT06109272
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) Solution
Trial: NCT06109272
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) Solution
Trial: NCT06109272
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) Solution
Trial: NCT06109272
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Solution
Trial: NCT05496686
Drug: 4.7 microCi 225Ac-MTI-201
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.7 microCi intravenous solution
Trial: NCT05496686
Drug: 9.5 microCi of 225Ac-MTI-201
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.5 microCi intravenous solution
Trial: NCT05496686
Drug: 19 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 microCi intravenous solution
Trial: NCT05496686
Drug: 38 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 microCi intravenous solution
Trial: NCT05496686
Drug: 76 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 76 microCi intravenous solution
Trial: NCT05496686
Drug: 152 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 152 microCi intravenous solution
Trial: NCT05496686
Drug: 254 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 254 microCi intravenous solution
Trial: NCT05496686
Drug: 424 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 424 microCi intravenous solution
Trial: NCT05496686
Drug: 564 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 564 microCi intravenous solution
Trial: NCT05496686
Drug: 750 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 microCi intravenous solution
Trial: NCT05496686
Drug: 998 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 998 microCi intravenous solution
Trial: NCT05496686
Drug: 1327 microCi of 225Ac-MTI-201
RxNorm normalized name: Oil of peppermint
DrugBank: MTI-201 (DB17169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1327 microCi intravenous solution
Trial: NCT05353257
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W
Trial: NCT05353257
Drug: carboplatin/cisplatin-etoposide
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice.
Trial: NCT06237920
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
Trial: NCT06237920
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
Trial: NCT05753930
Drug: Imlifidase
RxNorm normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Trial: NCT05008484
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000IU oral vitamin D supplementation daily for 9 months
Trial: NCT04971785
Drug: Cilofexor (CILO)/Firsocostat (FIR)
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05153668
Drug: Everolimus Oral Tablet
RxNorm normalized name: everolimus Oral Tablet
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
Trial: NCT04902443
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.
Trial: NCT04902443
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
Trial: NCT05662904
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
Trial: NCT05061719
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 42 mg capsules administered orally, once daily
Trial: NCT05909761
Drug: UPLIZNA
RxNorm normalized name: Uplizna
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
Trial: NCT06168851
Drug: Anti-CD38 antibody Injection
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Trial: NCT05944562
Drug: Tulmimetostat
RxNorm normalized name: Tulmimetostat
DrugBank: Tulmimetostat (DB19446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
Trial: NCT06391853
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Trial: NCT05578976
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection (SC)
Trial: NCT05578976
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT05578976
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05578976
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT05579249
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
Trial: NCT05579249
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Trial: NCT05579249
Drug: Phentermine/Topiramate
RxNorm normalized name: PHENTERMINE/TOPIRAMATE
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Trial: NCT05579249
Drug: Naltrexone/Bupropion
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Trial: NCT05579249
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Trial: NCT06515470
Drug: BTX-9341
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
Trial: NCT06515470
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscular injections on Day 15 and then every 28 days
Trial: NCT06515470
Drug: BTX-9341
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Daily oral dose in 28-day cycles using dose determined in Part A
Trial: NCT06522386
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT06522386
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT06522386
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by mouth
Trial: NCT05929794
Drug: Metronidazole 0.75% Topical Gel
RxNorm normalized name: Metronidazole 0.75% Topical gel
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
Trial: NCT05929794
Drug: Metronidazole 0.75% Topical Cream
RxNorm normalized name: Metronidazole 0.75% Topical cream
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
Trial: NCT06023862
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT06023862
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT06023862
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT06023862
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT06648889
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.
Trial: NCT06648889
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
Trial: NCT04982848
Drug: Talzenna
RxNorm normalized name: Talzenna
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talzenna treatment under Korea regulatory approval indication/dosage
Trial: NCT05579730
Drug: Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: combination ophthalmic solution
Trial: NCT05579730
Drug: Brimonidine Tartrate 0.025%
RxNorm normalized name: BRIMONIDINE TARTRATE 0.025% OPH SOLN
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ophthalmic Solution
Trial: NCT05579730
Drug: Ketotifen Fumarate 0.035%
RxNorm normalized name: KETOTIFEN FUMARATE 0.035% SOLN,OPH
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ophthalmic Solution
Trial: NCT04771130
Drug: BGB-11417
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Trial: NCT04771130
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous or subcutaneous administration for 7 days.
Trial: NCT04771130
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration for 8 days on second cycle only.
Trial: NCT04771130
Drug: BGB-11417
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 28 days on a 28-day cycle.
Trial: NCT04771130
Drug: BGB-11417
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 10, 14 or 21 days on a 28-day
Trial: NCT06405230
Drug: Pemetrexed+ (carboplatin or cisplatin)
RxNorm normalized name: Cisplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
Trial: NCT06596473
Drug: BG-C477
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT06611111
Drug: Ceftriaxone (Rocephin®)
RxNorm normalized name: ceftriaxone Injection [Rocephin]
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slightly yellow liquid.
Trial: NCT05630183
Drug: Botensilimab
RxNorm normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Trial: NCT05630183
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-of-care chemotherapy administered intravenously.
Trial: NCT05630183
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-of-care chemotherapy administered intravenously.
Trial: NCT06387199
Drug: Semaglutide with 4 meal strategies
RxNorm normalized name: semaglutide 4 MG
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.